Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of pembrolizumab versus placebo with definitive chemoradiotherapy for esophageal cancer
CTR20200717Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in esophageal cancer, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Merck & Co.. Started Jul 2020; status: terminated.
02
Drugs
03
Conditions
esophageal cancergastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20200717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200717.